The European Medicines Agency (EMA) issued an opinion on Kayshild with the active substance semaglutide, which is an agonist of the GLP-1 receptor[1][4]. Semaglutide acts like the GLP-1 hormone produced in the gut, increasing the release of insulin from the pancreas in response to food and helping to control blood glucose levels[4]. In five studies of more than 4,000 patients with type 2 diabetes, Ozempic (semaglutide) reduced HbA1c by 1.2 to 1.8 percentage points over 10 to 13 months, which was better than sitagliptin (0.55), exenatide (0.92), insulin glargine (0.83), or placebo (up to 0.09)[4]. The treatment led to weight loss, which is beneficial for diabetics, and reduced the risk of complications such as myocardial infarction or stroke[4]. Animal studies have shown that semaglutide reduces the development of atherosclerosis by preventing the progression of aortic plaque and reducing the inflammatory response[1][3]. Clinical data have confirmed the reduction of albuminuria in patients with kidney disease[1]. The safety profile is consistent with other drugs in this class, with manageable side effects on the digestive system; worsening of diabetic retinopathy will be further investigated[4]. The EMA concluded that the benefits outweigh the risks and recommended approval for use in the EU[4].